Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Targeting TP53 promotes anti-leukemia immunity and enhances CD70 CAR-T efficacy in AML by transcriptionally upregulating CD70

View Full Paper
Ask AI
Bookmark
Share

Authors

YSYuan SongYLYun LiKBKaranpreet Singh Bhatia

Discussion

Loading...

Member takes

Overview

Genome-wide CRISPR screen identified TP53's role in CD70 regulation, suggesting it as a biomarker for immunotherapy in AML.

Key Points

  • TP53 activation improves CD70 expression and enhances anti-tumor immunity in leukemia.
  • Notably, CD70 CAR-T efficacy is higher in TP53 wild-type acute myeloid leukemia cells.
  • Using chromatin immunoprecipitation, p53 was shown to directly activate CD70 transcription.
  • Retrospective analysis suggests TP53 status could inform immunotherapy strategies in AML.

Cite This Study

Song et al. (2025) studied this question.

synapsesocial.com/papers/69362f3d4fa91c937236d498https://doi.org/10.1182/blood-2025-2349
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Abstract P03: Chemotherapy-Induced CD70 Expression Enhances Anti-Tumor Immunity and CAR-T Cell Efficacy in Acute Myeloid Leukemia2026
  2. 2TNF-α and IFN-γ differentially regulate AML cell susceptibility to CD70-antibody-mediated cytotoxicity2025 · 3 citations
  3. 3Targeting DNA repair vulnerabilities to eradicate TP53 mutated AML.2025
  4. 4Non-hematotoxic Tim-3/CD70 dual-targeting CAR T cells promote potent anti-leukemia activity against acute myeloid leukemia2025 · 1 citations
  5. 5Impact of TP53 mutation on CD19-chimeric antigen receptor T-cell therapy in large B-cell lymphoma2025